[Hyperbaric oxygenation in the treatment of patients with interstitial cystitis: clinical and morphological rationale].

We studied efficacy of hyperbaric oxygenation (HBO) in 8 patients with interstitial cystitis/painful bladder syndrome (IC/PBS). Mean age of the patients was 53 years (35-72 years), mean duration of the disease 7.5 years (6-17 years). Ulcerative IC/PBS was diagnosed in 7 of 8 patients. The patients received combined treatment: surgical (hydrobouginage of the bladder, electrocoagulation of bladder ulcer) and a HBO course in the postoperative period. The efficacy was assessed by clinical and morphological criteria (estimation of histamine level in urethral smears, proliferative activity of bladder mucosa epithelial cells). A HBO course consisted of 10 sessions (40 min, 2 atm). The treatment reduced the number of voidings for 24 hours, increased mean effective bladder volume, lowered a total score by L. Parsons scale, histamine content in urethral smears, stimulated proliferative activity of bladder mucosa epithelium. Thus, HBO proved its safety and effectiveness in combined treatment of IC/PBS.

[Prophylaxis of recurrences of urinary tract infection].

Canephron N, a medicine of plant origin, was tested in outpatient aftertreatment for prophylaxis of recurrent infection of the upper urinary tract, in intravesical therapy for prophylaxis of lower urinary tract infections in sexually transmitted diseases. Canephron N provides an additional anti-inflammatory and symptomatic effect which lasts after active antibacterial therapy, and effective antibacterial protection in invasive manipulations, intravesical instillations, in particular. The drug showed good tolerance.

[Prostaplant treatment of benign prostatic hyperplasia]. / Lechenie dobrokachestvennoi giperplazii predstatel'noi zhelezy preparatom prostaplantom.

80 patients aged 48 to 91 years with verified benign prostatic hyperplasia (BPH) stage I and II, having contraindications to surgery, received prostaplant, extract of Sabal serrulata palm fluit, in a dose 320 mg once a day. The treatment resulted in improvement of subjective and objective parameters (the total IPSS score improved by 32.3%, quality of life by 36.4%; maximal urine flow rate by 27.4%, respectively). Residual urine volume reduced in patients of group I by 26.8%, in patients of group II by 25.5%. The drug tolerance was good. 3 patients failed treatment. Good and satisfactory effects were achieved in 69 and 8 patients, respectively. Therefore, prostaplant is effective in BPH.

Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.

This 3-month double-blind, randomized, parallel-group study compared the efficacy and tolerability of two regimens of the lipido-sterolic extract of Serenoa repens (Permixon) (two 160-mg capsules once daily [OD] and one 160-mg capsule twice daily [BID]) in 100 outpatients with symptomatic benign prostatic hyperplasia (BPH). Both regimens significantly (P < .0001) reduced the International Prostate Symptom Score (I-PSS) mean total score from baseline; improvements achieved statistical significance after the first month and were maintained for the duration of the study. Significant (P < .05) and rapid improvements from baseline to the end of month 1 also occurred in I-PSS quality-of-life (QoL) scores, maximum and mean urinary flow rates, and residual urine volume; this benefit was further increased at month 3 for I-PSS total score and QoL and residual volume, and was maintained for maximum and mean flow rates. A highly significant decrease (P < .001) in residual urine was observed in both groups. No significant differences were noted between regimens. Clinical adverse events occurred at a similar incidence in both groups (BID, 24%; OD, 22%) and were deemed unrelated or unlikely to be related to Permixon.